Ptc Therapeutics (PTCT) Enterprise Value (2012 - 2026)

Ptc Therapeutics' Enterprise Value history runs 15 years deep, the most recent figure standing at -$1.9 billion for Q1 2026.

• On a quarterly basis, Enterprise Value rose 6.65% year-over-year to -$1.9 billion in Q1 2026; TTM through Mar 2026 was -$1.9 billion, a 6.65% increase from a year earlier, with the FY2025 full-year figure at -$1.9 billion, down 70.69% from the prior year.
• Enterprise Value improved to -$1.9 billion in Q1 2026 per PTCT's latest filing, from -$1.9 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$286.3 million in Q1 2023 and bottomed at -$2.0 billion in Q1 2025.
• The 5-year median for Enterprise Value is -$884.8 million (2024), against an average of -$1.0 billion.
• Across the five-year window, Enterprise Value jumped 66.77% in 2022 and plunged 243.73% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$410.7 million in 2022, then tumbled by 113.47% to -$876.7 million in 2023, then retreated by 29.99% to -$1.1 billion in 2024, then plunged by 70.69% to -$1.9 billion in 2025, then grew by 2.72% to -$1.9 billion in 2026.
• Per Business Quant, the three latest PTCT Enterprise Value figures stand at -$1.9 billion (Q1 2026), -$1.9 billion (Q4 2025), and -$1.7 billion (Q3 2025).